Home > ATLAS Project Research Members
ATLAS Project Research Members
National Cancer Center Hospital (Tokyo, Japan)
NISHIKAWA Tadaaki (Depertment of Medical Oncology)
NISHIKAWA Tadaaki MD, PhD
Dr. NISHIKAWA's story
I have strong interest in the development of drug therapies for gynecologic cancer.
Research interests
Gynecologic Cancer
Professional Experiences
- 2021- Present Staff Physician, Department of Medical Oncology, National Cancer Center Hospital
- 2019- 2021 Staff Physician, Department of Breast and Medical Oncology, National Cancer Center Hospital
- 2017-2019 Department of Gynecologic Oncology, Saitama Medical University International Medical Center
- 2015-2017 Chief Resident, Department of Breast and Medical Oncology, National Cancer Center Hospital
- 2010-2015 Department of Gynecologic Oncology, Saitama Medical University International Medical Center
Selected publications
- Suzuki M, Yagishita S, Sugihara K, Ogitani Y, Nishikawa T, Ohuchi M, et al. Visualization of intra-tumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. Clin Cancer Res. 2021:clincanres.0397.2021
- Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, et al. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precision Oncology. 2021(5):756-66.
- Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Archiv : an international journal of pathology. 2021.
- Watanuki R, Shimomura A, Yazaki S, Noda-Narita S, Sumiyoshi-Okuma H, Nishikawa T, et al. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. Medicine (Baltimore). 2020;99(38):e22331.
- Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, et al. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology. 2020;98(10):699-705.
- Yano M, Asami Y, Nishikawa T, Yoshida S, Kamada K, Katoh T, et al. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report. Medicine (Baltimore). 2018;97(43):e12937.
- Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, et al. PIK3CA mutation profiling in
patients with breast cancer, using a highly sensitive detection system. Cancer Sci. 2018;109(8):2558-66. - Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, et al. Phase 1 dose-escalation study of
single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017;108(9):1834-42. - Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, et al. Utility of Bayesian Single-Arm
Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Ther Innov Regul Sci. 2018;52(3):334-8. - Nishikawa T, Hasegawa K, Yabuno A, Yoshida H, Yasuda M, Kozawa E, et al. Pazopanib as a second line
treatment for uterine and ovarian carcinosarcoma: a single institutional study. J Gynecol Oncol. 2017;28(1):e25.
Link
- National Cancer Center Hospital Department of Medical Oncology: https://www.ncc.go.jp/jp/ncch/clinic/medical_oncology/index.html